Pharmaceutical Product Deck

About this template

Ten slides that carry product information

The agenda runs composition and formulation, mechanism of action, old versus new formulation, key metrics and the trend chart – five items. The center of gravity is transcribing the label accurately rather than debating clinical evidence, which fits internal product training, a briefing for clinicians, or a detailing visit. It is the wrong shape for a symposium oral session or consumer material. The closing line, “check the label before prescribing”, says the same thing.

Flow, and the topics you have to add yourself

Ten slides: cover, agenda, two divider-plus-body pairs, comparison, four metric cards, a bar chart, and a closing slide. The body slides are titled composition and formulation, and mechanism of action. Only the first two agenda lines own a divider-plus-body pair; the third is the comparison slide 7 and the last two are slides 8 and 9. Put the other way round, indications, dosage, safety information and reimbursement appear neither in the agenda nor on any slide. Safety information in particular is mandatory in many settings, so duplicate the 5-6 pair, build at least one slide for it and add the agenda line. The four metric cards stand in for these topics one tile at a time, and four tiles do not discharge a disclosure obligation.

Filling the two body slides

1. Slide 4, composition and formulation. Ships with a single-ingredient 10mg film-coated tablet, once-daily oral dosing, domestic approval in March 2025 – active ingredient and strength, dosage form, approval date. For a combination product, list each ingredient’s strength and state the salt form.
2. Slide 6, mechanism of action. Selective receptor antagonism, peak plasma concentration at 2 hours, 14-hour half-life supporting once-daily dosing. One mechanism line followed by two pharmacokinetic lines that explain why it is once daily; if you change the half-life, change the dosing sentence with it.
3. Both slides carry a one-line lead under the title. Keep any wording that is not in the label out of that line.

The metric cards and the time-axis bars

The four cards read daily dose 10mg, half-life 14 hours, headache incidence 8.4%, ceiling price KRW 1,180 per tablet – dosing, pharmacokinetics, safety and reimbursement, compressing topics with no slide of their own onto a single slide. Footnote which trial and which arm the headache figure comes from, and date the ceiling price (e.g. as of the January 2026 notice) because it changes. Slide 9 already has a time axis: week 4 at 22, week 12 at 41, week 24 at 58, week 52 at 66. Nothing states what is rising, so put the axis unit and population in the caption, for example response rate in percent, treatment arm, by visit. The gentle rise to week 52 suits a maintenance-of-effect message, but if your observation is shorter, delete the later bars. The bars are shapes, so resize by (value / largest value).

Rules for the numbers

• Pair any efficacy figure with a confidence interval; a p value alone hides the effect size.
• Do not let one card be the whole safety story; add a table of the most frequent adverse events.
• Keep off-label indications and head-to-head claims out; depending on the venue they trigger review.
• Re-check the reimbursement notice on the day you present; redistributed decks keep old prices alive for years.

What gets challenged afterwards

• Leaving the figures on slide 7 (three doses a day down to one, adherence 62% to 89%) unchecked against the approved label. Dosing and adherence claims have to stay inside the approved indication and cite the study behind them; until you have that, delete the slide.
• Promoting a subgroup finding into the cards. Keep the age-group observation in the body and reserve the cards for label-level figures.
• Selling once-daily convenience while omitting contraindicated combinations and dose adjustment in renal or hepatic impairment. That is the first question from the floor.